|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 921.75 INR | -1.04% |
|
-1.51% | -5.08% |
| 12-04 | Zydus Lifesciences Gets US FDA's Establishment Inspection Report for Jarod, India Unit | MT |
| 12-04 | Zydus Lifesciences receives EIR for injectable facility located at Jarod | RE |
| Capitalization | 937B 10.41B 8.95B 8.39B 7.82B 14.44B 15.7B 98.09B 37.87B 443B 39.09B 38.25B 1,619B | P/E ratio 2026 * |
20.6x | P/E ratio 2027 * | 22.7x |
|---|---|---|---|---|---|
| Enterprise value | 938B 10.42B 8.95B 8.39B 7.82B 14.44B 15.71B 98.12B 37.88B 443B 39.1B 38.26B 1,619B | EV / Sales 2026 * |
3.64x | EV / Sales 2027 * | 3.22x |
| Free-Float |
24.85% | Yield 2026 * |
0.75% | Yield 2027 * | 0.72% |
Last Transcript: Zydus Lifesciences Limited
| 1 day | -0.98% | ||
| 1 week | -1.51% | ||
| Current month | -2.14% | ||
| 1 month | -2.75% | ||
| 3 months | -8.65% | ||
| 6 months | -5.27% | ||
| Current year | -5.08% |
| 1 week | 920.35 |  | 947 |
| 1 month | 920.35 | | 973 |
| Current year | 795 | | 1,059.05 |
| 1 year | 795 | | 1,059.05 |
| 3 years | 403.2 | | 1,324.3 |
| 5 years | 319 | | 1,324.3 |
| 10 years | 202 | | 1,324.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 46 | 26/11/2009 | |
| Director of Finance/CFO | 64 | - | |
| Director of Finance/CFO | 55 | 31/08/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 46 | 31/03/2007 | |
| Director/Board Member | 70 | 31/07/1997 | |
| Chairman | 72 | 04/10/2011 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0.01% | 51 M€ | +4.72% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.04% | -1.51% | -6.12% | +123.84% | 10.41B | |
| -0.88% | -0.96% | -0.92% | +82.51% | 48.13B | |
| +0.21% | +5.69% | +4.51% | +102.78% | 31.13B | |
| +3.22% | +5.08% | +57.18% | - | 30.86B | |
| -1.60% | -1.63% | +1.99% | +35.28% | 13.65B | |
| -2.12% | -2.18% | +81.68% | +83.72% | 9.54B | |
| -0.49% | -0.98% | +47.99% | +113.98% | 7.16B | |
| -.--% | +0.14% | - | - | 6.79B | |
| +0.83% | -0.40% | +23.93% | -38.00% | 6.36B | |
| -2.74% | -1.34% | +26.51% | +344.20% | 6.17B | |
| Average | -0.44% | -0.35% | +26.31% | +106.04% | 17.02B | |
| Weighted average by Cap. | -0.01% | +0.20% | +19.97% | +93.85% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 258B 2.86B 2.46B 2.31B 2.15B 3.97B 4.32B 26.97B 10.41B 122B 10.75B 10.52B 445B | 272B 3.03B 2.6B 2.44B 2.27B 4.2B 4.56B 28.51B 11.01B 129B 11.36B 11.12B 470B |
| Net income | 46.36B 515M 443M 415M 387M 714M 777M 4.85B 1.87B 21.89B 1.93B 1.89B 80.05B | 41.42B 460M 396M 371M 345M 638M 694M 4.33B 1.67B 19.56B 1.73B 1.69B 71.53B |
| Net Debt | 263M 2.92M 2.51M 2.35M 2.19M 4.05M 4.41M 27.54M 10.63M 124M 10.97M 10.74M 454M | -59.48B -661M -568M -532M -496M -916M -997M -6.23B -2.4B -28.09B -2.48B -2.43B -103B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/12/25 | 921.75 ₹ | -1.04% | 508,758 |
| 05/12/25 | 931.45 ₹ | -0.46% | 892,186 |
| 04/12/25 | 935.75 ₹ | +0.09% | 874,529 |
| 03/12/25 | 934.95 ₹ | -0.82% | 1,158,530 |
| 02/12/25 | 942.70 ₹ | +0.67% | 823,400 |
Delayed Quote NSE India S.E., December 08, 2025 at 09:27 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ZYDUSLIFE Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition